Peptide Atlas · Mineral

Ferric derisomaltose (iron isomaltoside 1000)

In the IRONMAN trial of 1,137 patients with heart failure and iron deficiency, intravenous ferric derisomaltose lowered recurrent heart failure admissions and cardiovascular death against usual care (rate ratio 0.82), short of statistical significance except in a pre-specified COVID-19 sensitivity analysis.

established

provisional
2 citations
0 discussions
0 followers
Monofer
Monoferric
ferric derisomaltose
iron isomaltoside 1000

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

established — replicated in humans, or settled by a regulator

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

Evidence, kept apart

The Atlas never mixes evidence types into one blob. Each claim below carries the tier it actually sits in; an unresolved citation is shown and does not move the page.

Evidence map for Ferric derisomaltose (iron isomaltoside 1000). Tier reflects study design, not enthusiasm.
Claim	Tier	Source
Iron isomaltoside causes much less hypophosphatemia than ferric carboxymaltose (two RCTs)	established	pmid 32016310
Ferric derisomaltose in heart failure with iron deficiency (IRONMAN RCT)	established	pmid 36347265

Unanswered questions

No open questions on file. Either everything about this molecule is known, or nobody has admitted what is not.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.